• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国甲状腺癌放射性碘治疗成年患者的患者准备及辐射防护指南

Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK.

作者信息

Wadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L, Craig A J, Farnell K, Garcez K, Garnham N, Graham K, Hallam A, Hill S, Hobrough H, McKiddie F, Strachan M W J

机构信息

Weston Park Cancer Centre, Sheffield, UK.

Northern Centre for Cancer Care, Newcastle, UK.

出版信息

Clin Oncol (R Coll Radiol). 2023 Jan;35(1):42-56. doi: 10.1016/j.clon.2022.07.002. Epub 2022 Aug 24.

DOI:10.1016/j.clon.2022.07.002
PMID:36030168
Abstract

Radioactive iodine is a highly effective treatment for thyroid cancer and has now been used in clinical practice for more than 80 years. In general, the treatment is well tolerated. However, it can be logistically quite complex for patients due to the need to reduce iodine intake and achieve high levels of thyroid-stimulating hormone prior to treatment. Radiation protection precautions must also be taken to protect others from unnecessary radiation exposure following treatment. It has been well documented by thyroid cancer patient support groups that there is significant variation in practice across the UK. It is clear that some patients are being asked to observe unnecessarily burdensome restrictions that make it more difficult for them to tolerate the treatment. At the instigation of these support groups, a multidisciplinary group was assembled to examine the evidence and generate guidance on best practice for the preparation of patients for this treatment and the management of subsequent radiation protection precautions, with a focus on personalising the advice given to individual patients. The guidance includes advice about managing particularly challenging situations, for example treating patients who require haemodialysis. We have also worked together to produce a patient information leaflet covering these issues. We hope that the guidance document and patient information leaflet will assist centres in improving our patients' experience of receiving radioactive iodine. The patient information sheet is available as Supplementary Material to this article.

摘要

放射性碘是治疗甲状腺癌的一种高效疗法,现已在临床实践中使用了80多年。一般来说,这种治疗的耐受性良好。然而,由于在治疗前需要减少碘摄入量并使促甲状腺激素达到高水平,这对患者来说在安排上可能相当复杂。治疗后还必须采取辐射防护措施,以保护他人免受不必要的辐射暴露。甲状腺癌患者支持组织已有充分记录表明,英国各地的实际做法存在显著差异。很明显,一些患者被要求遵守不必要的繁重限制,这使他们更难耐受治疗。在这些支持组织的鼓动下,成立了一个多学科小组来审查证据,并就患者接受该治疗的准备工作以及后续辐射防护措施的管理制定最佳实践指南,重点是为个体患者提供个性化建议。该指南包括有关处理特别具有挑战性情况的建议,例如治疗需要血液透析的患者。我们还共同编写了一份涵盖这些问题的患者信息手册。我们希望该指南文件和患者信息手册将有助于各中心改善我们患者接受放射性碘治疗的体验。患者信息表作为本文的补充材料提供。

相似文献

1
Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK.英国甲状腺癌放射性碘治疗成年患者的患者准备及辐射防护指南
Clin Oncol (R Coll Radiol). 2023 Jan;35(1):42-56. doi: 10.1016/j.clon.2022.07.002. Epub 2022 Aug 24.
2
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.甲状腺癌的低剂量碘 131 消融联合促甲状腺激素治疗。
N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.
3
Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.接受碘-131治疗甲状腺癌患者的辐射剂量率。
Eur J Nucl Med. 1996 Feb;23(2):123-30. doi: 10.1007/BF01731834.
4
Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.131I 放射性碘治疗甲状腺疾病患者的辐射安全:美国甲状腺协会的实践建议。
Thyroid. 2011 Apr;21(4):335-46. doi: 10.1089/thy.2010.0403. Epub 2011 Mar 18.
5
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.低剂量碘-131 消融联合重组人促甲状腺激素治疗分化型甲状腺癌后复发(HiLo):一项开放标签、非劣效性随机对照临床试验的长期结果。
Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51. doi: 10.1016/S2213-8587(18)30306-1. Epub 2018 Nov 27.
6
Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.儿童甲状腺癌与放射性碘治疗:谨慎进行辐射健康风险管理的必要性
Endocr J. 2007 Dec;54(6):839-47. doi: 10.1507/endocrj.k07e-012. Epub 2007 Oct 15.
7
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.重组人促甲状腺素辅助放射性碘消融及分化型甲状腺癌的治疗:综述
Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830.
8
Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.氨磷汀、左旋肉碱和维生素E在预防放射性碘治疗引起的早期唾液腺损伤中的辐射防护作用
Curr Med Imaging Rev. 2019;15(4):395-404. doi: 10.2174/1573405614666180314150808.
9
Restrictions following iodine-131 treatment--a time for change or more data required?碘-131治疗后的限制——是时候改变了还是需要更多数据?
Eur J Nucl Med. 1994 Sep;21(9):903-5. doi: 10.1007/BF00238112.
10
Radioiodine treatment for malignant thyroid disease.放射性碘治疗恶性甲状腺疾病。
Acta Oncol. 2006;45(8):1041-5. doi: 10.1080/02841860600617076.

引用本文的文献

1
Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis.重组人促甲状腺素用于分化型甲状腺癌放射性碘治疗后的中长期复发:一项荟萃分析
Front Endocrinol (Lausanne). 2024 Dec 17;15:1474121. doi: 10.3389/fendo.2024.1474121. eCollection 2024.
2
Determination of effective half-life of I in thyroid cancer patients using remote dose-rate meter.使用远程剂量率仪测定甲状腺癌患者中碘的有效半衰期
EJNMMI Phys. 2024 Nov 29;11(1):101. doi: 10.1186/s40658-024-00701-8.
3
LINC00261 triggers DNA damage via the miR-23a-3p/CELF2 axis to mitigate the malignant characteristics of I-resistant papillary thyroid carcinoma cells.
LINC00261通过miR-23a-3p/CELF2轴触发DNA损伤,以减轻碘难治性甲状腺乳头状癌细胞的恶性特征。
Biochem Biophys Rep. 2024 Oct 30;40:101858. doi: 10.1016/j.bbrep.2024.101858. eCollection 2024 Dec.
4
Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial.重组人促甲状腺激素联合放射性碘治疗甲状腺癌患者的非劣效性随机临床试验。
JAMA Netw Open. 2024 Nov 4;7(11):e2443407. doi: 10.1001/jamanetworkopen.2024.43407.
5
Initial results of the INSPIRE clinical trial-investigating radiation dosimetry for differentiated thyroid cancer patients.INSPIRE临床试验的初步结果——针对分化型甲状腺癌患者的放射剂量测定研究。
Front Nucl Med. 2023 May 15;3:964478. doi: 10.3389/fnume.2023.964478. eCollection 2023.
6
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.放射性碘治疗晚期甲状腺癌中治疗前定量成像和剂量学的作用。
J Nucl Med. 2023 Jul;64(7):1125-1130. doi: 10.2967/jnumed.122.264913. Epub 2023 Apr 28.